Pacific Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.25M Sell
1,942
-315
-14% -$372K 1.7% 23
2026
Q2
$2.71M Buy
2,257
+1,150
+104% +$1.17M 2.34% 20
2026
Q1
$1.02M Buy
+1,107
New +$1.12M 1% 31
2025
Q1
– Sell
-1,246
Closed -$962K – 55
2024
Q4
$962K Hold
1,246
– – 0.57% 42
2024
Q3
$1.1M Hold
1,246
– – 0.65% 38
2024
Q2
$1.13M Hold
1,246
– – 0.75% 41
2024
Q1
$969K Hold
1,246
– – 0.63% 44
2023
Q4
$726K Buy
1,246
+22
+2% +$12.8K 0.55% 48
2023
Q3
$657K Buy
+1,224
New +$631K 0.4% 44

Other funds holding LLY

Pacific Capital Partners's LLY Position: Q3 2026 in Review

Pacific Capital Partners reduced its Eli Lilly (LLY) stake by 14% in Q3 2026, selling an estimated $372K and leaving 1,942 shares worth $2.25M. The position accounts for 1.7% of the portfolio, ranked #23.

Pacific Capital Partners first reported a position in LLY in Q3 2023 and has held it in 9 quarters since. The position peaked at $2.71M in Q2 2026. 4,625 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Pacific Capital Partners held 1,942 shares of Eli Lilly worth $2.25M as of Q3 2026.
  • Pacific Capital Partners sold 315 Eli Lilly shares in Q3 2026, an estimated $372K.
  • Eli Lilly made up 1.7% of Pacific Capital Partners's portfolio in Q3 2026, its #23 holding.
  • Pacific Capital Partners first reported a position in Eli Lilly in Q3 2023 and has held it in 9 quarters since.
  • Pacific Capital Partners's Eli Lilly position peaked at $2.71M in Q2 2026.
  • 4,625 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Pacific Capital Partners's 13F filing for Q3 2026, filed 28 Oct 2026.